Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis.
People
James Mullen (President, CEO)
Cecil Picket (President, R&d)
Paul Clancy (Executive VP, CFO)
Lawrence Best (Board Member)
Marjin Dekkers (Board Member)
News
Life-science briefing: Monday, March 24, 2008
March 24, 2008 8:17 pm
TODAY’S HEADLINES: Trius Therapeutics raises $30M for new antibiotics (release) Genomas gets $1.2M grant for genomic side-effect tests (release) Provasculon… Continue reading ⟩
Life sciences briefing: Tuesday, Jan. 8, 2008
January 8, 2008 11:02 pm
TODAY’S HEADLINES: CyberHeart pumps in $9M for cardiac-arrhythmia treatment (release) Incubator ForSight launches third device company with $6M funding (release)… Continue reading ⟩
Life sciences briefing: Thursday, Jan. 3, 2008
January 4, 2008 2:49 am
TODAY’S HEADLINES: Gelesis draws in $16M for obesity treatments (release) Tempo Pharma raises $8B for nanoparticle drugs (release) Calistoga Pharma… Continue reading ⟩